Spondyloarthritis & psoriatic arthritis
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events
Authors' conclusion
MACE risk does not significantly differ across bDMARD classes in patients with PsO/PsA.
Study context
- Population
- Patients with psoriasis or psoriatic arthritis (PsA) who were new bDMARD users, TriNetX database; Psoriasis (PsO)/PsA for a mean of 3.5 (SD 4.5) years before starting a biologic
- Participants
- 32,758 new bDMARD users
- Exposure
- IL-17Ai, IL-23i or IL-12/23i vs tumor necrosis factor inhibitors (TNFi)
- Outcome
- MACE
Methodological detailsnew-user design, weighted multinomial Cox proportional hazards regression, negative control outcome
- New-user design
- Weighted multinomial Cox proportional hazards regression
- Negative control outcome
Main finding
As reported in the abstract
Adjusted hazard ratio (95% CI)
IL-17Aivs TNFi
0.98(0.73–1.32)
IL-23ivs TNFi
0.84(0.54–1.31)
IL-12/23ivs TNFi
1.08(0.80–1.47)
Observational data: associations, not effects.
Further findings
Components of major adverse cardiac events (MACE) and baseline CVD (subset analyses)
- Subset analyses supported the primary analysis
Negative control outcome
- Suggested adequate control of bias confounding
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Choice of Biologic Immunotherapy for Psoriasis or Psoriatic Arthritis and Its Association With Risk of Major Adverse Cardiac Events. J Rheumatol. Published 1 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →